Pharmalot blog posting
The biotech gets a chance to say ‘I told you so.’ A letter posted on its web site and addressed to healthcare professionals says there 36 reports of off-label use in Canada last month that resulted in adverse events, 32 of which were serious. Genentech goes on to make the point that its Avastin cancer med, which was being used to treat wet maculer degeneration, was not approved for “use…in the ophthalmology setting.”